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re hope this report will help highlight scientific papers
ublished in the year 2005 that have focused on interven-
ional cardiology (Table 1). In addition, we have included
ate-breaking trials presented at the American College of
ardiology, Transcatheter Cardiovascular Therapeutics,
nd American Heart Association Conferences. We hope
hat the paper will provide a broad overview of the field for
eneral cardiologists and an organized outline for detailed
tudy for those with a specific interest in interventional
ardiology. Finally, we have asked the I2 Summit Steering
ommittee members to help us select the top ten articles of
he year.
CUTE MYOCARDIAL INFARCTION (AMI)
n 2005, most interest was focused on studies designed to
valuate the role of percutaneous coronary intervention
PCI) after initial treatment with thrombolytic therapy.
escue PCI for failed thrombolysis. Although PCI is
idely accepted as the best initial treatment strategy for
atients with AMI, there has been controversy about the
enefit of PCI in patients with failed thrombolysis. In the
reviously reported Middlesbrough Early Revascularization
o Limit Infarction (MERLIN) trial, PCI resulted in a
odest reduction in ischemia-driven revascularization;
owever, stroke and transfusions were more common in the
escue PCI group, and there was no difference in mortality
1). Results of the larger Rescue Angioplasty versus Con-
ervative Treatment or Repeat Thrombolysis (REACT)
rial were published in 2005 (2). Patients with lack of
T-segment resolution 90 min after thrombolysis (n 427)
ere randomized to three arms: rescue PCI, repeat throm-
olysis using tissue-type plasminogen activator or reteplase,
r conservative care. The primary end point of combined
eath, reinfarction, stroke, or severe heart failure within six
onths was significantly reduced in the rescue PCI arm
15.3%) compared with 31.0% in the repeat thrombolysis
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ccepted February 8, 2006.rm, and 29.8% with conservative care (p  0.001). This
enefit was due to reduction in death, reinfarction, and
eart failure. Moreover, significantly less ischemia-driven
evascularization was required in the rescue PCI arm. These
ata suggest that patients with failed thrombolysis should
ndergo rescue stenting.
mmediate PCI after thrombolysis. Prior clinical guide-
ines discouraged routine angioplasty after thrombolysis
ecause of historical (but outdated) studies suggesting an
xcess risk of complications in these patients. Since then,
ignificant advances in mechanical and pharmacological
herapy have occurred. In the Combined Angioplasty and
harmacological Intervention versus Thrombolysis Alone in
cute Myocardial Infarction (CAPITAL AMI) study, te-
ecteplase plus immediate angioplasty was found to be
uperior to tenecteplase alone in 170 high-risk ST-segment
levation myocardial infarction (STEMI) patients (3). Ma-
or adverse cardiac events (MACE) were significantly re-
uced at six months in the tenecteplase-PCI group (11.6%
s. 24.4%, p  0.04), largely due to reductions in recurrent
nstable ischemia and reinfarction. There was no increase in
he incidence of major bleeding. Thus, in the era of stents
nd newer antiplatelet agents, routine PCI after thrombol-
sis is not only safe, but improves outcomes and thus may be
referable to “watchful waiting.”
Among patients who are selected to undergo delayed
oronary angiography and intervention after thrombolysis,
arly pre-treatment with clopidogrel appears to be benefi-
ial. In the PCI-Clopidogrel as Adjunctive Reperfusion
herapy (CLARITY) study, 1,863 patients underwent PCI
wo to eight days after thrombolysis for AMI (4). At 30
ays, pre-treatment with clopidogrel not only reduced
einfarction and stroke before PCI, but improved the
ombined end point of cardiovascular death, myocardial
nfarction, or stroke after PCI (3.6% vs. 6.2%, p  0.008).
his difference was observed despite recommending a load-
ng dose of open-label clopidogrel to be administered in the
ath lab for placebo patients, and use of glycoprotein
Ib/IIIa inhibitors at the operator’s discretion.
acilitated PCI. For patients with anticipated delay to
CI, there has been tremendous interest in using pharma-
ologic agents before PCI to achieve early infarct vessel
atency and therefore improve clinical outcomes. However,
esults of the Assessment of the Safety and Efficacy of a
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The Year in Interventional Cardiology April 18, 2006:1689–706able 1. Glossary of Interventional Cardiology Trials Published or Presented in 2005
Acronym Trial
MISTAD-2 Acute Myocardial Infarction Study of Adenosine
RMYDA-2 Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty
RTS Arterial Revascularization Therapies Study
SPIRE Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation
SSENT-4 Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction
STAMI Effects on left ventricular function by intracoronary injections of autologous mononuclear bone marrow cells in acute
anterior wall myocardial infarction
ASKET Basel Stent Kosten Effektivitäts Trial
RAVE-2 Bavarian Reperfusion AlternatiVes Evaluation-2
APITAL AMI Combined Angioplasty and Pharmacological Intervention versus Thrombolytics ALone in Acute Myocardial Infarction
LEAR PLATELETS Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets
REATE-ECLA Clinical Trial of Metabolic Modulation in Acute Myocardial Infarction Treatment Evaluation-Estudios Cardiológicos
Latinoamérica
REST Cilostazol for Restenosis Trial
IABETES Diabetes and Sirolimus-Eluting Stent
IRECT Direct myocardial revascularization In Regeneration of Endomyocardial Channels
REAM Dutch Randomized Endovascular Aneurysm Management
ASY A prospective randomized trial of transradial PCI with bolus abciximab versus bolus abciximab plus infusion
MERALD Enhanced Myocardial Efficacy and Removal by Aspiration of Liberated Debris
NDEAVOR-II A prospective, randomized comparison of the ABT-578-coated Driver stent with a bare stent
NDEAVOR-III A prospective, randomized comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with coronary artery
disease
RACI Argentine randomized study: coronary angioplasty with stenting versus coronary bypass surgery in multivessel disease
UROINJECT Direct Intramyocardial Plasmid Vascular Endothelial Growth Factor-A160 Gene Therapy in Patients with Stable Severe
Angina Pectoris
VAR Endovascular Aneurysm Repair
IRSTLINE-AMI Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Granulocyte
Colony-Stimulating Factor
CTUS Invasive versus Conservative Treatment in Unstable Coronary Syndromes
SAR-CHOICE Intracoronary Stenting and Antithrombotic Regimen: Choose between 3 high Oral doses for Immediate Clopidogrel
Effect
SAR-DIABETES Intracoronary Stenting and Angiographic Results: Do Diabetic Patients Derive Similar Benefit from Paclitaxel-Eluting
and Sirolimus-Eluting Stents
SAR-DESIRE Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for In-Stent Restenosis
SAR-TEST A prospective, randomized trial of the Yukon non-polymer-based rapamycin-coated stent and the polymer-based
paclitaxel-eluting stent in patients with coronary artery disease
IPS-2 Glucose-Insulin-Potassium study in patients with ST elevation myocardial infarction without signs of heart failure
UMBO-TIMI 26 Joint Utilization of Medications to Block Platelets Optimally
UPITER-2 A prospective randomized trial of a tacrolimus-eluting stent compared to a carbon-coated stent in patients with coronary
artery disease
E MANS A prospective randomized trial of stent implantation vs bypass graft surgery in patients with left main coronary artery
disease
CI-CLARITY PCI-Clopidogrel as Adjunctive Reperfusion Therapy
REVENT-4 PRoject of Ex-Vivo Vein Graft ENgineering via Transfection
RIDE Protection During Saphenous Vein Graft Intervention to Prevent Distal Embolization
RISON-II A prospective randomized trial of sirolimus-eluting and bare metal stents in patients with chronic total occlusions
ROMISE Protection Devices in PCI Treatment of Myocardial Infarction for Salvage of Endangered Myocardium
ROXIMAL Proximal Protection During Saphenous Vein Graft Intervention Using the Proxis Embolic Protection System
EACT Rescue Angioplasty versus Conservative Treatment or Repeat Thrombolysis
EALITY Randomized multicenter head-to-head comparison of the sirolimus-eluting stent (Cypher) and the paclitaxel-eluting stent
(Taxus)
EMEDIA Randomized Evaluation of the Effect of Mechanical Reduction of Distal Embolization by Thrombus-Aspiration in
Primary and Rescue Angioplasty
EPAIR AMI Intracoronary infusion of bone marrow-derived progenitor cells in acute myocardial infarction: a randomized, double-
blind, placebo-controlled multicenter trial
ESEARCH Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital
EVIVAL-2 A prospective randomized, double-blind trial of granulocyte colony stimulating factor in patients with acute myocardial
infarction
CANDSTENT Stenting of coronary arteries in non-Stress/Benestent disease
ENIOR-PAMI A prospective randomized trial of primary angioplasty and thrombolytic therapy in elderly patients with acute myocardial
infarction
IRTAX Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization
ISR Sirolimus-eluting stent vs. Intravascular Brachytherapy in the Treatment of Patients with In-stent Restenotic Coronary
Lesions
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April 18, 2006:1689–706 The Year in Interventional CardiologyASSENT)-4 trial, presented at the European Society of
ardiology and American Heart Association, demonstrated
hat facilitated PCI with full-dose tenecteplase was harmful
ompared to primary PCI alone (5). In this trial 1,667
atients with STEMI 6 h from symptom onset with
nticipated door-to-balloon time of90 min were random-
zed to facilitated PCI (with full-dose tenecteplase) or
rimary PCI alone. The trial was prematurely terminated by
he data and safety monitoring board due to a higher 30-day
ortality in the facilitated PCI arm (6.6 vs. 3.6%, p 
.013). The primary end point (death, congestive heart
ailure, or shock at 90 days) was significantly higher in the
acilitated PCI arm compared with primary PCI (18.6% vs.
3.4%, p  0.005). There was also a higher rate of stroke
ith facilitated PCI (2.65% vs. 0.12%, p  0.0001). Based
n the results of this trial, one should not use thrombolytics
o “facilitate” reperfusion before immediate PCI.
CI versus thrombolysis. The optimal reperfusion strat-
gy for elderly patients with AMI has not been well defined
6). The Senior Primary Angioplasty in Myocardial Infarc-
ion (PAMI) trial randomized 483 elderly (70 years old)
atients who were thrombolytic-eligible to primary PCI
ersus thrombolytic with low-dose heparin (60 U/kg) (7).
he trial was stopped early by the DSMB due to difficulty
ecruiting. The primary end point of death or disabling
troke at 30 days was 11.3% and 13.0% (pNS) in the PCI
nd thrombolytic arms, respectively, and the secondary end
oint of death, reinfarction, or disabling stroke was 11.6%
nd 18% (p  0.05). A substantial benefit was seen in
atients between age 70 and 80 (37% reduction in death,
5% reduction in death, myocardial infarction, or stroke
p  0.001]). However, among patients 80 years of age,
he prognosis was grim in both the PCI and thrombolytic
rms (death 19% vs. 16%, p  0.72; death, reinfarction, or
troke, 22% vs. 22%, p 0.96). This trial highlights the risk
hat age alone poses and demonstrates that an optimal
eperfusion strategy for patients80 years is still undefined.
rimary PCI. Few studies have evaluated whether me-
hanical reperfusion is beneficial in patients who present
12 h from symptom onset. The Bavarian Reperfusion
lternatives Evaluation (BRAVE)-2 investigators random-
zed 365 patients with STEMI (between 12 to 48 h from
ymptom onset) to PCI with abciximab versus conservative
are (8). Infarct size measured by sestamibi was smaller in
able 1 Continued
Acronym
PIDER Saphenous Vein Graft Protection In a Dista
TRATEGY Single High Dose Bolus Tirofiban and Sirol
Infarction
AXi A prospective randomized comparison between
AXUS-V Comparison of a polymer-based paclitaxel-elut
AXUS-VI Prospective, multicenter, randomized trial of
iNOX Randomized comparison of a titanium-nitrid
AMINE ST X-Sizer in AMI for Negligible Embolizationhe invasive group compared with the conservative care proup (8% vs. 13%, p  0.001), and there was a non-
ignificant improvement in combined death, myocardial
nfarction, or stroke (4.4 vs. 6.6%, p  0.37). These data
uggest that asymptomatic STEMI patients may benefit
rom mechanical reperfusion, well beyond the traditional
2-h window.
Although stenting during primary PCI has been shown
o reduce restenosis and reocclusion compared with PTCA,
ard end points have not been improved. Mehta et al. (9)
ollowed 2,087 patients who underwent primary PCI in the
AMI trials, of whom 692 received stents. Stenting resulted
n better angiographic and short-term clinical outcomes, but
lso a sustained beneficial effect on mortality at five years.
ime-to-treatment. The National Registry of Myocardial
nfarction (NRMI)-4 study has demonstrated that PCI
herapy has equaled and surpassed thrombolytic therapy for
reatment of STEMI in the U.S. Along with this wide-
pread acceptance of PCI therapy, attention has turned to
ow to optimize results and expand availability to patients
resenting to hospitals without PCI capability. Herrmann
10) nicely summarized the adverse impact of delays in
ransfer. In an analysis from the NRMI 3/4 registries,
allamothu et al. (11) found that only 4% of 4,278 patients
ransferred for PCI were treated within 90 min of initial
resentation. De Luca et al. (12) further outlined the
dverse impact of time-to-treatment and found that infarct
ize and one-year mortality were substantially worse in
atients with treatment delay. Treatment delay is not only
n issue for transfer patients, but is also an important
roblem for off hours and weekend presentation. Magid
t al. (13) reported the outcome of 33,647 patients treated
ith PCI from 1999 to 2002. He found that door-to-
alloon times exceeding 120 min were more common
uring off hours. During this interval, 54% of patients were
reated off hours. The median door-to-balloon time was 116
in during off hours and 94 min during working hours.
n-hospital mortality was significantly higher during off
ours (p  0.02). These reports outline in stark detail the
uboptimal system for PCI therapy that currently exists in
he U.S. It is heartening to report that Bradley et al. (14)
utlines concrete steps, and in particular the role of local
hysician champions, to improve treatment delays. These
eports are a call to action in every community to improve
Trial
bolic Protection Randomized Trial
Eluting Stent vs Abciximab and Bare Metal Stent in Myocardial
itaxel and sirolimus stents in the real world of interventional cardiology
ent with a bare metal stent in patients with complex coronary artery disease
olymer-based paclitaxel-eluting stent in patients with de novo lesions
de-coated stent with a stainless steel stent for coronary revascularization
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The Year in Interventional Cardiology April 18, 2006:1689–706herapies and devices to enhance myocardial salvage. The
uest to identify new pharmacologic or mechanical adjuncts
o reperfusion therapy continues. Results of nine studies
ere reported or published in 2005 (Table 2).
The Acute Myocardial Infarction Study of Adenosine
AMISTAD)-2 trial investigated whether intravenous
denosine administered before reperfusion would reduce
nfarct size or improve clinical outcomes (15). Patients
eceiving thrombolysis or primary PCI were randomized to
3-h infusion of adenosine (50 or 70 g/kg/min) or
lacebo. There was no difference in the primary end point
new congestive heart failure, or first rehospitalization for
ongestive heart failure, or death within six months). How-
ver, a smaller infarct size was observed in the high-dose
denosine arm, suggesting a potential treatment effect.
Results of the Effect of Glucose-Insulin-Potassium Infu-
ion on Mortality in Patients with Acute ST-Segment
levation Myocardial Infarction (CREATE-ECLA) trial
able 2. Interventional Trials in Acute Myocardial Infarction in
Study Design
djunctive therapies to enhance myocardial salvage
AMISTAD-II (15) Anterior AMI 6 h. Randomly
assigned to receive a 3-h infusion
of adenosine (50 or 70 g/kg/
min) or placebo.
CREATE-ELCA (16) AMI 12 h Randomized to receive
GIK intravenous infusion for
24 h or to usual care alone.
2
GIPS II (17) AMI without signs of heart failure.
Randomized to receive high-dose
GIK or usual care.
Ishii et al. (18) AMI. Randomized to receive 12
mg of intravenous nicorandil or
placebo just before reperfusion.
djunctive thrombectomy or embolic protection
REMEDIA (19) AMI 12 h. Randomized before
coronary angiography to PCI
with manual thrombus-aspiration
or PCI alone.
XAMINE-ST (20) AMI 12 h. TIMI flow 0 or 1 at
baseline. Randomized to stenting
with or without thrombectomy
using the X-Sizer device
Kaltoft et al.* (21) STEMI. Randomized to PCI plus.
thrombectomy (Rescue catheter)
or PCI alone.
EMERALD (22) AMI 6 h. Randomized to PCI
with distal protection using the
GuardWire device or PCI alone.
PROMISE (23) Patients with NSTEMI or STEMI
48 h. Randomized to PCI with
or without distal protection using
the FilterWire.
Trial presented at scientific meeting but not yet published.
AMI  acute myocardial infarction; GIK  glucose-insulin-potassium infusion; P
egional wall motion; STR  ST-segment resolution.ave now settled the question of whether glucose-insulin- lotassium (GIK) improves mortality in AMI patients (16).
n this trial (the largest study of GIK therapy), 20,201
atients with STEMI presenting within 12 h from symp-
om onset were randomized to receive high-dose GIK
nfusion for 24 h or usual care. Approximately 1,800
atients in the trial were treated with primary PCI. At 30
ays, there was no difference in all-cause mortality (control
.7% vs. GIK 10.0%, p  0.45), or any secondary outcome
easures including cardiac arrest, cardiogenic shock, or
einfarction. Similarly, in the Glucose-Insulin-Potassium
tudy in Patients with ST Elevation Myocardial Infarction
ithout Signs of Heart Failure (GIPS)-2 trial, treatment
ith high-dose GIK in STEMI patients without signs of
eart failure did not reduce infarct size or mortality (17).
Intravenous nicorandil, a potassium channel opener and
itric oxide donor, has been shown to improve coronary
rtery flow and ST-segment resolution, when administered
ust before reperfusion. In 2005, Ishii et al. (18) reported
Primary Study End Point Principal Results
Death, new heart failure, or
first hospitalization for
CHF within 6 months
No difference in clinical outcomes
with adenosine. Final infarct
size was smaller in the high-
dose adenosine group.
Mortality at 30 days GIK infusion had no effect on
mortality or any secondary
outcome measures.




Lower rate of clinical events in
the nicorandil arm at mean
follow-up of 2.4 yrs. Improved
post PCI TIMI flow 3 and
STR in nicorandil group.
Post-PCI TMPG 2 and
STR (70%)
Higher rate of post-PCI TMPG
2 and STR in manual
aspiration group.
STR 1 h after PCI More complete ST-segment
resolution and lower incidence
of distal embolization in the
X-Sizer group.
Myocardial salvage at 30
days
Trend toward higher salvage in
PCI alone arm. Larger final
infarct size in pts treated with
thrombectomy.
Infarct size by SPECT
imaging 5–14 days. STR
30 min after PCI.




Doppler flow velocity in
the infarct related artery
post PCI
No difference in Doppler flow
velocity, or infarct size (MRI)
with filter-based distal
protection.
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April 18, 2006:1689–706 The Year in Interventional Cardiologyzed trial and found that patients treated with nicorandil had
lower incidence of cardiovascular death or hospital admis-
ion with congestive heart failure.
The year 2005 was largely disappointing for proponents
f thrombectomy or distal protection during infarct angio-
lasty. Two studies published this year reported positive
utcomes with thrombectomy in AMI, while a third trial
eported worse outcomes in thrombectomy-treated patients.
n the Randomized Evaluation of the Effect of Mechanical
eduction of Distal Embolization by Thrombus-Aspiration
n Primary and Rescue Angioplasty (REMEDIA) trial, use
f the manual aspiration Diver catheter (Invatec S.r.l.,
rescia, Italy) before stent implantation was associated with
mproved ST-segment resolution and myocardial perfusion
19). Similarly, in the X-SIZER in Acute Myocardial
nfarction Patients for Negligible Embolization and Opti-
al ST Resolution (X AMINE ST) trial, adjunctive throm-
ectomy with the X-Sizer device (eV3, Plymouth, Minne-
ota) led to better ST-segment resolution (20). In contrast,
altoft (21) found that patients who were treated with the
oston Scientific Rescue device (Mountain View, Califor-
ia) had significantly larger final infarct size at 30 days
ompared with patients treated with PCI alone.
Continuing this theme, two studies evaluating use of
istal protection devices reported negative results. In the
nhanced Myocardial Efficacy and Removal by Aspiration
f Liberated Debris (EMERALD) trial, the GuardWire
alloon occlusion and aspiration system (Medtronic, Santa
osa, California) was used for embolic protection during
CI (22). Although visible debris was retrieved in 70% of
ases treated with the protection device, this was not
ssociated with any improvement in final Thrombolysis
n Myocardial Infarction (TIMI) flow, myocardial per-
usion, infarct size, or clinical events. In the Protection
evices in PCI-Treatment of Myocardial Infarction for
alvage of Endangered Myocardium (PROMISE) trial, a
istal filter was used to limit distal embolization, but this
ailed to improve maximal adenosine-induced Doppler
ow velocity in the infarct-related artery post-PCI or
nfarct size by magnetic resonance imaging (MRI) (23).
aken together, these data suggest that there is no role for
outine use of thrombectomy or distal protection during
echanical reperfusion. Whether these devices are useful in
atients with a large thrombus burden needs further inves-
igation.
ell-based cardiac repair after AMI. Use of stem cell
echniques to enhance myocardial recovery after AMI was
vidly investigated in 2005. The REPAIR-AMI random-
zed 204 AMI patients in a multicenter trial conducted in
ermany and Switzerland (24). All patients underwent
rimary PCI with stenting followed by bone marrow aspi-
ation four to five days later. Aspirates were sent to a central
ab that processed the cells and sent back in a blinded
ashion either mononuclear progenitor cells (average 236
illion cells) or placebo. The infusions were given into thenfarct artery through an inflated balloon catheter. At four Ponths, greater improvement in ejection fraction was ob-
erved in the stem cell group (5.5% vs. 3%, p  0.014), and
linical events were slightly but not significantly improved.
mprovement in ejection fraction was confined to subgroup
ith baseline ejection fraction 49%, and those treated
ore than five days after myocardial infarction. The Effects
n Left Ventricular Function by Intracoronary Injections of
utologous Mononuclear Bone Marrow Cells in Acute
nterior Wall Myocardial Infarction (ASTAMI) trial ran-
omized 101 patients with anterior AMI treated with
tenting within 12 h of symptom onset (25). Patients
eceived either intracoronary autologous mononuclear bone
arrow cells five to eight days after myocardial infarction or
ontrol. Left ventricular function was assessed at baseline
nd at six months by three methods: single-photon emission
omputed tomography, echocardiography, and MRI. There
ere no significant differences between the two groups in
ny of these measurements. In fact, MRI suggested a trend
or greater improvement of ejection fraction in the control
roup. Another small study enrolled 35 patients with AMI
reated with stenting. Although a slight improvement in
jection fraction was noted, administration of stem cells was
omplicated by increased coronary events (26). Among the
9 patients receiving intracoronary stem cells (CD133
rogenitor cells), in-stent reocclusion was noted in 2 pa-
ients, restenosis in 7 patients, and de-novo lesions in the
nfarct artery occurred in 2 patients. In the control group,
nly four cases of in-stent restenosis were observed.
It was hoped that subcutaneous injections of granulocyte
olony stimulating factor (G-CSF) would be a simple
oninvasive method of improving left ventricular function
fter AMI because it causes liberation of cells from the bone
arrow thus increasing circulating stem cells. However,
-CSF also greatly increases circulating white blood cells
nd platelets, the effects of which in the setting of a recent
MI are unknown. The Front-Integrated Revascularization
nd Stem Cell Liberation in Evolving Acute Myocardial
nfarction by Granulocyte Colony Stimulating Factor
FIRSTLINE-AMI) investigators reported data on 50
atients treated with G-CSF for six days versus no G-CSF
fter primary stenting plus abciximab (27,28). Patients
reated with G-CSF had improved wall motion, left ven-
ricular end-diastolic diameter, and ejection fraction. How-
ver, the Prospective Randomized, Double-Blind Trial of
ranulocyte Colony Stimulating Factor in Patients with
cute Myocardial Infarction (REVIVAL)-2 found that
-CSF did not improve ejection fraction or infarct size
easured by single-photon emission computed tomography
nd MRI at six months (29). In this trial, 114 AMI patients
ith successful PCI and baseline infarct size of at least 5%
ere randomized to G-CSF or placebo for five days.
lthough there was no improvement in infarct size or
yocardial recovery, restenosis rates were not increased with
-CSF. Reports of potential complications with G-CSF
ave also surfaced. In one study, seven patients undergoing
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The Year in Interventional Cardiology April 18, 2006:1689–706rowth (30). Two of the seven patients developed acute
oronary occlusion. A second study administered G-CSF
or five days to stimulate collateral growth in 16 patients
ith refractory angina (31). Two of 16 patients suffered
MI, one of which was fatal. Whether these events were
ue to thrombocytosis, and whether more potent antiplate-
et therapy would have reduced this risk is unknown.
In summary, studies published in 2005 provide conflict-
ng, although somewhat promising, data on the role of stem
ell infusion after reperfusion therapy. The exact mecha-
isms of action, cell type, infusion protocol, and methods of
ssessing efficacy remain major challenges in this field.
ardiogenic shock. Despite advances in PCI techniques
nd adjunctive care, the prognosis for AMI patients who
evelop cardiogenic shock is dismal. Klein et al. (32) studied
he outcomes of 483 shock patients in the American College
f Cardiology-National Cardiovascular Data registry who
nderwent PCI. Although PCI was successful in 79% of
atients, the in-hospital mortality was 59.4%. In addition,
lein et al. (32) developed a useful model to predict
n-hospital mortality, based on four key pre-procedural
ariables (age, female gender, history of renal insufficiency
creatinine 2.0 mg/dl], and total occlusion of the left
nterior descending coronary artery). Babaev et al. (33)
eported trends in management and outcomes of shock
atients among 293,633 patients in the NRMI. From 1995
o 2004, there was an increase in PCI rates for shock
atients from 27.4% to 54.4%. Overall in-hospital mortality
or shock decreased from 60.3% to 47.9%. In a propensity-
djusted multivariable analysis, PCI was associated with
mproved in-hospital survival. In a report from the Should
e emergently revascularize Occluded Coronaries in cardio-
enic shock (SHOCK) group, White et al. (34) highlighted
he importance of coronary artery bypass graft surgery
CABG) as a revascularization strategy for shock patients
ith extensive coronary artery disease. Finally, Dzavik et al.
35) reported on the outcomes of 56 patients age 75 years
n the randomized SHOCK trial. Although patients who
nderwent early revascularization had a higher mortality
ompared with patients in the initial medical stabilization
rm, there was an important imbalance in baseline charac-
eristics in the initial medical stabilization group, including
igher ejection fraction (35.6% vs. 27.5%, p  0.051) and
ower rate of anterior infarction (40.6% vs. 62.5%, p 
.11). Based on these data, and favorable results from
everal other registries, PCI is reasonable to consider in
elected patients 75 years or older who develop shock within
6 h of AMI.
CUTE CORONARY SYNDROMES (ACS)
everal studies, which randomized ACS patients to early
nvasive versus conservative therapy, have shown clinical
enefits to invasive treatment. One-year follow-up of the
hird Randomized Intervention Trial of unstable Angina
RITA-3) found reduced angina and improved quality of wife with invasive therapy (36). Five-year follow-up demon-
trated a sustained reduction in death or myocardial infarc-
ion (odds ratio 0.78, p  0.044) (37). A meta-analysis of
even trials comparing routine versus selective invasive
trategies in ACS found that the invasive strategy was
ssociated with reduced myocardial infarction, severe an-
ina, and rehospitalization (38). Although there was a
igher early mortality in the invasive arm, after discharge
here were significantly fewer deaths. A larger meta-analysis
f 10 trials, which randomized 9,990 patients, demon-
trated a reduced rate of death or myocardial infarction
ith the invasive strategy (odds ratio  0.79, p  0.01)
nd a non-significant decrease in mortality (39). These
nvestigators found that aggressive antiplatelet therapy (p 
.005) and stenting (p  0.01) were the most significant
redictors of benefit.
The most recent trial randomized 1,200 patients with
CS admitted to hospitals in the Netherlands to early
nvasive versus selective invasive strategies (40). Although
ehospitalization in the invasive group was reduced at one
ear (7.4% vs. 10.9%, p  0.04), there was an increased risk
f myocardial infarction (15.0% vs. 10.0%, p  0.005),
esulting in no difference in the primary end point of death,
yocardial infarction, or rehospitalization. The increase in
yocardial infarction observed in the trial may have been
ue in part to the liberal definition of periprocedural
nfarction.
CI FOR CHRONIC CORONARY ARTERY DISEASE
CI versus medical therapy or CABG. Compared with
alloon angioplasty, coronary stent implantation has im-
roved procedural success, decreased acute occlusion, need
or emergency bypass, and the risk of restenosis. For these
easons, stent therapy has become the dominant method of
ercutaneous revascularization. Operators now routinely
ntervene in patient and lesion subsets that previously were
he domain of cardiac surgeons. The year 2005 provided us
ith the first long-term results of comparative efficacy of
are-metal stents (BMS) versus coronary artery bypass
urgery. Serruys et al. (41) reported the five-year follow-up
f 1,205 patients with multivessel disease randomized to
MS or bypass. At five years, mortality (8% vs. 7.6%, p 
S) and freedom from death, stroke, and myocardial
nfarction (18.2% vs. 14.9%, p  NS) were similar for stent
r bypass patients. Target vessel revascularization (TVR)
as higher for the stent group (30.3% vs. 8.8%, p  0.001),
nd a trend to higher mortality occurred in the subgroup of
08 patients with diabetes treated with stents (13.4% vs.
.3%, p  0.27). Rodriguez et al. (42) reported strikingly
imilar five-year results from the 450 patients treated in the
rgentine Randomized Trial of Coronary Angioplasty with
tenting versus Coronary Bypass Surgery in Patients with
ultivessel Disease (ERACI) II. Mortality and freedom
rom death/myocardial infarction were similar, but TVR
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CI versus CABG. Hannan et al. (43) described 37,212
atients with multivessel disease treated with bypass or stent
herapy in New York State between 1997 and 2000.
alenka et al. (44) reported the outcomes in 14,493
atients with multivessel disease treated in Northern New
ngland from 1994 to 2001. Both registries suggest a
isk-adjusted survival advantage for CABG-treated patients
ith three-vessel disease. The New York study also sug-
ested a three-year risk-adjusted survival advantage for
atients with two-vessel disease and proximal left ante-
ior descending coronary artery involvement who were
reated with CABG. In addition, both registries report
ignificantly higher TVR rates for stent patients. These
ong-term results provide fuel for controversy about the
ong-term impact of drug-eluting stents (DES) versus
ABG in surgical candidates. This controversy will only
e settled by long-term data from randomized trials that
re now being conducted.
CI for chronic total occlusion (CTO). Chronic total
cclusion remains a challenge in the field of PCI. McLellan
t al. (45) reviewed long-term follow-up data on 2,056
atients from the Alberta outcomes project. In this report,
48 patients had persistent total occlusions and were in-
ompletely revascularized. At three-year follow-up, a 25%
ncrease in the risk of death and a 45% increase in the risk
f bypass occurred for patients with incomplete revascular-
zation. Thus, methods to treat CTO continue to draw
nterest. Stone et al. (46,47) published two consensus papers
n PCI for CTO, which nicely summarized the field.
inally, Abbas et al. (48) reported on a new technique to
acilitate treatment of CTO. They describe use of an 8-h
nfusion of low-dose tenecteplase or alteplase in 85 patients
ho had previously failed standard CTO recanalization
echniques and found a 54% success rate in these refrac-
ory cases. Leon et al. (49) took a different approach by
andomizing patients with incomplete revascularization
o direct laser transmyocardial laser revascularization
MR versus sham therapy in the Direct myocardial
evascularization In Regeneration of Endomyocardial
hannels (DIRECT) trial. Patients were randomized to
ow-dose, high-dose myocardial laser channels, or sham.
aser-treated patients had a higher rate of 30-day myo-
ardial infarction and no improvement in anginal status
r exercise duration compared to control.
actors influencing clinical outcomes after elective PCI.
he most modifiable risk factor for complications and
ortality after PCI is the skill and experience of the
perative team. Hannan et al. (50) report that in the New
ork State database of 107,713 PCIs performed between
998 to 2000 that low-volume operators (75 cases/year)
orking in low-volume hospitals (400 cases/year) had a
ix-fold increase in the risk of same-day bypass and a
our-fold increase in the risk of death compared with
igh-volume operators and hospitals. Similarly, Moscucci et
l. (51) examined the Michigan Blue Cross consortium tutcome data and found that MACE events were signifi-
antly higher for operators doing 89 cases per year (p 
.0001). These two studies provide strong incentives to
imit the unbridled expansion of PCI facilities.
Cram et al. (52) studied whether opening of cardiac
urgical hospitals might improve outcomes. They report on
he Medicare database during 2000 and 2001 when 69,000
atients had PCI or CABG in 15 specialty hospitals.
utcomes were compared with patients treated in general
ospitals. Volumes were greater for both PCI and CABG in
he specialty hospitals, and unadjusted 30-day mortality was
ower. The mortality differences largely disappeared after
isk adjustment. They concluded that specialty hospitals
ave improved outcomes due to case selection and higher
rocedural volumes.
Moscucci et al. (53) further provide provocative data
uggesting that high-risk patients may be orphaned by
ublic reporting. They reviewed the outcome experience in
ew York State where public reporting is state mandated
nd in Michigan where it is not, for the years 1998 and
999. Crude unadjusted mortality was higher in Michigan
1.54% vs. 0.83%, p  0.0001). After adjusting for comor-
idities, no difference in mortality existed. More patients
ith cardiogenic shock (14.4% vs. 8.7%, p  0.001), conges-
ive heart failure, and extracardiac vascular disease were
reated in Michigan. The authors conclude that public
eporting in New York may cause patient selection bias that
recludes treatment of high-risk patients.
Further data is accumulating on the adverse risk that
hronic kidney disease (CKD) poses for PCI patients. Ix et
l. (54) describe 290 patients who had CKD and were
reated with PCI (n  151) or bypass (n  139) in the
rterial Revascularization Therapies Study (ARTS)-I. Ma-
or adverse cardiac events were significantly greater for both
CI and CABG patients when CKD was present. Simi-
arly, Lemos et al. (55) reported that mortality at one year
as greater (7.6% vs. 2.5%) for patients with CKD with no
ifference whether or not DES were employed. Target
essel revascularization was reduced by DES implantation
relative risk  0.37, confidence interval  0.15 to 0.90,
 0.03). Finally, Dangas et al. (56) reported that contrast-
nduced nephropathy dramatically escalates one-year mor-
ality in PCI patients with CKD. Importantly, a 75%
ne-year mortality occurred for patients with CKD that
equired new dialysis because of contrast-induced nephrop-
thy. These trials all continue to draw attention to this
igh-risk population and this potentially lethal complication
f PCI.
ell and subcellular therapies for chronic ischemia.
lthough intracoronary infusion of stem cells may be
eneficial after recent AMI, patients with remote infarction
r chronic angina no longer release chemotactic factors
llowing homing of stem cells to the affected area. There-
ore, most studies have utilized needle injections of stem
ells for chronic angina or heart failure. The Direct In-
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ngina Pectoris (EUROINJECT-One) trial was a double
lind, randomized trial of 80 patients with class 3 to 4
ngina who received either intramyocardial injections of
lasmid vascular endothelial growth factor A or placebo
57). Procedure-related adverse events occurred in 5 of 40
atients (12.5%) randomized to plasmid vascular endothelial
rowth factor A. At three months, there was no difference
n stress myocardial perfusion defects between the two
roups. Interestingly, vascular endothelial growth factor
ene transfer improved regional wall motion and angina
lass, suggesting a favorable anti-ischemic effect even
hough the primary end point was negative. Strauer et al.
58) reported results in 18 patients with remote myocardial
nfarction (five months to eight years earlier) in whom bone
arrow cells were infused through an inflated balloon
atheter in the coronary artery. At three months, infarct size
as reduced by 30%, ejection fraction improved by 15%, no
rrhythmias were observed, and only one patient developed
estenosis.
New technologies to affect endothelial healing are being
nvestigated. The Healthy Endothelial Accelerated Lining
nhibits Neointimal Growth (HEALING) registry treated
6 patients with de-novo coronary disease with a stainless
teel stent coated with murine monoclonal CD-34 antibod-
es (59). This stent captures endothelial progenitor cells
ith in-vivo studies showing 90% coverage at 1 h,
llowing inhibition of thrombus formation and reduced
eointimal proliferation. In this 16-patient registry, no
atient experienced subacute thrombosis despite discontin-
ation of clopidogrel at day 28. At six-month angiography,
estenosis occurred in two patients (13%), and late loss was
.63  0.52 mm. The HEALING II registry will test
ewer stent technology with greater preservation of anti-
ody structure and bioactivity.
igure 1. Clinical outcome in patients treated with a sirolimus-eluting o
eta-analysis of published randomized trials of paclitaxel vs. sirolimus stents. A
ubacute thrombosis; TLR  target lesion revascularization.The PRoject of Ex-vivo Vein Graft ENgineering via
ransfection (PREVENT)-4 study randomized 3,014 pa-
ients undergoing CABG with at least two saphenous vein
rafts (SVG) to receive SVGs pretreated with placebo or
difoligide (transcription factor inhibitor intended to sup-
ress neointimal hyperplasia) (60). The primary end point
f death or SVG failure (stenosis 75%) in at least one
VG by angiography at 18 months was not reduced by
ranscription factor inhibition, whether measured per pa-
ient (45.2% vs. 46.3%, p  0.66) or per SVG (28.5% vs.
9.7%, p  0.44).
HERAPIES FOR THE PREVENTION OF RESTENOSIS
ES. COMPARATIVE TRIALS OF SIROLIMUS-ELUTING
TENTS (SES) VERSUS PACLITAXEL-ELUTING STENTS (PES).
n the year 2004, we witnessed the widespread adoption of
ES after approval of the Cypher (Johnson & Johnson) and
axus (Boston Scientific) systems in the U.S. Detailed
omparison of the two systems occurred in 2005. Kastrati et
l. (61) summarized the completed comparison trials. Kas-
rati et al. (62) also reported the Intracoronary Stenting and
ngiographic Results: Drug-Eluting Stents for In-Stent
estenosis (ISAR-DESIRE) trial in which 300 patients
ith in-stent stenosis were randomized to treatment with
rachytherapy (n  100), paclitaxel (n  100), or sirolimus
n  100). Dibra et al. (63) studied 250 patients with
iabetes who were randomized to paclitaxel (n  125) or
irolimus (n  125) in the Intracoronary Stenting and
ngiographic Results: Do Diabetic Patients Derive Similar
enefit from Paclitaxel-Eluting and Sirolimus-Eluting
tents (ISAR-DIABETES) trial. Goy et al. (64) studied
he seven-month clinical outcome of 202 patients treated
ith paclitaxel or sirolimus. In contrast with these small
rials, three large randomized trials were reported in 2005
ncluding Sirolimus-Eluting and Paclitaxel-Eluting Stents
litaxel-eluting stent. Data are summarized from the Kastrati et al. (61)r pac
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April 18, 2006:1689–706 The Year in Interventional Cardiologyor Coronary Revascularization (SIRTAX) (65), Prospec-
ive Randomized Multi-Center Head-to-Head Compari-
on of the Sirolimus-Eluting Stent (Cypher) and the
aclitaxel-Eluting Stent (Taxus) (REALITY) (66), and
rug-Eluting Stents for Complex Lesions: Randomized
apamycin Versus Paclitaxel (CORPAL) (67). These trials
andomized 1,012, 1,353, and 652 to SES or PES. Of these
rials, only the SIRTAX trial has been published (65). In the
astrati et al. (61) meta-analysis, all six trials were pooled to
escribe angiographic and clinical outcome for 3,669 patients
Fig. 1). At follow-up, mortality was 25 of 1,845 for the SES
roup versus 29 of 1,824 in the PES group (pNS). Death
r myocardial infarction occurred in 91 of 1,845 and 106 of
,824 for sirolimus- or paclitaxel-treated patients, respec-
ively (p  NS). Stent thrombosis was infrequent and
imilar for both groups (17 of 1,845 vs. 20 of 1,824, p 
S). Although major safety measures were similar, angio-
raphic results favored sirolimus; target lesion revasculariza-
ion (TLR) was 5.1% vs. 7.8% (p  0.001), and angio-
raphic restenosis was 9.3% versus 13.1% (p  0.001). Two
ther reports also demonstrated that the initial benefit of
ES is maintained at late follow-up (68,69). Because major
afety data were similar and TLR was low for both groups,
t is likely that other factors such as stent availability,
eliverability, and cost will play a larger role in stent
election in the U.S. in 2006.
ON–FDA-APPROVED DES. The Randomized Comparison of
he Endeavor ABT-578 Drug Eluting Stent With a Bare
etal Stent for Coronary Revascularization (ENDEAVOR)
I trial was a multicenter, international trial randomizing
,195 patients with de-novo coronary lesions to receive the
edtronic ABT-578 (a rapamycin analogue) Endeavor
tent versus the Medtronic Driver cobalt alloy stent (70).
he primary end point of target vessel failure at nine
onths (TVR, myocardial infarction, or cardiac death) was
educed in the DES group (8.1% vs. 15.4%, p  0.0005),
rimarily due to reduced TVR. Although restenosis rates
9.5% vs. 32.7%, p  0.0001) and late loss (0.62 mm vs.
.03 mm) were reduced with the Endeavor stent, it was not
s low as that observed with FDA-approved DES.
The Randomized Comparison of Zotarolimus-Eluting
nd Sirolimus-Eluting Stents in Patients With Coronary
rtery Disease (ENDEAVOR)-III trial randomized 436
atients to receive the Endeavor DES versus the Cypher
ES (71). Although MACE was similar, TLR tended to be
igher with the Endeavor stent (6.3% vs. 3.5%), and
n-segment late loss was significantly greater (0.34 mm vs.
.13 mm, p  0.001), as was in-stent late loss (0.60 mm vs.
.15 mm, p 0.001) and in-stent restenosis (9.2% vs. 4.3%,
 0.04). Medtronic has embarked on another trial,
hich will randomize 1,548 patients to Endeavor versus
he Taxus PES.
The Yukon Nonpolymer-Based Rapamycin-Coated Stent
nd the Polymer-Based Paclitaxel-Eluting Stent in Patientsith Coronary Artery Disease (ISAR-TEST) trial ran- oomized 450 patients to receive the Yukon DES (Translu-
ina, Hechingen, Germany), which has a microporous
urface coated with rapamycin (polymer-free) compared
ith the polymer-based paclitaxel stent (72). At nine-
onth follow-up, clinical outcomes were similar. Angio-
raphic restenosis was 14.2% versus 15.5% (p  0.73),
n-stent late loss 0.48 mm versus 0.48 mm, and in-segment
ate loss was 0.34 mm versus 0.24 mm (p  0.09) in the
on–polymer- and polymer-based stents, respectively.
he investigators concluded that the antirestenotic effect
f the Yukon DES was not inferior to that of the Taxus
olymer-based DES.
The Tacrolimus-Eluting Stent Compared to a Carbon-
oated Stent in Patients With Coronary Artery Disease
JUPITER) II trial randomized 332 patients to receive the
olymer-free Janus Tacrolimus-eluting Carbo stent (Sorin
iomedica Cardio, Saluggia, Italy) (drug reservoirs on outer
urface of stent) versus the Tecnic Carbostent (Sorin Bio-
edica Cardio) (73). Although there was a trend for
eduction in TLR and restenosis in the Janus group,
ngiographic follow-up at six months demonstrated no
ifference in late loss. Whether this disappointing result was
ue to a better than expected outcome in the bare stent
ersus the drug or eluting kinetics is unknown.
A small study randomized 42 patients to receive an
verolimus-eluting stent (n  27) versus a BMS (n  15)
74). At six-month angiographic follow-up, everolimus
ignificantly reduced late loss (0.10 mm vs. 0.85 mm, p 
.0001), and there was no stent thrombosis or aneurysm
ormation. The late loss of 0.1 mm is similar to sirolimus;
oth drugs have the same pathway to inhibit smooth muscle
ell proliferation.
By the end of 2005, 27 randomized trials have been
onducted comparing BMS to DES. The impact of angio-
raphic late loss is summarized in Figure 2. In aggregate,
hese trials suggest that an efficacy boundary of a late loss of
.6 mm exists. Because randomization to BMS is unlikely in
he future, it is likely that an efficacy target of angiographic
ate loss will become a performance standard (75).
TENT THROMBOSIS WITH DES. A series of articles in 2005
ddressed the safety of DES. Hwang et al. (76) suggested
hat intraluminal clot decreases paclitaxel absorption in a rat
odel. Whether this translates to decreased efficacy or
orse safety in patients with AMI is currently being tested
n the Harmonizing Outcomes with Revascularization and
tents (HORIZONS) trial. A concern has been voiced
egarding the incidence of subacute thrombosis in patients
reated with DES. To address this issue, Bavry et al. (77)
ooled data from eight randomized trials of PES versus
lacebo, while Moreno et al. (78) pooled data from 10
andomized trials of SES and PES. Both studies found that
ubacute thrombosis was low and similar for DES and BMS
ystems.
One mechanism for late stent thrombosis may be initial
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hrombosis after Cypher stent implantation. Rather than
tent malapposition, stent under expansion was present in
ost cases of subacute thrombosis. Tanabe et al. (80)
eported intravascular ultrasound findings in the Taxus II
rial. Late stent malapposition occurred in 5.4% of BMS
nd 8.7% of paclitaxel stents (p  NS). Late malapposition
as not associated with subacute thrombosis. Intravascular
ltrasound follow-up in the Sirolimus-coated Bx Velocity
alloon-Expandable Stent (SIRIUS) trial demonstrated a
igher rate of late acquired malapposition in Cypher-treated
atients (0% vs. 8.7%, p  0.05), but as in the TAXUS II
rial, no adverse clinical events occurred with late stent
alapposition (81). For this reason, other mechanisms for
ate subacute thrombosis have been studied. Ong et al.
82,83) reported that termination of dual antiplatelet ther-
py exacerbates risk of subacute thrombosis, as long as 14.5
onths after stent implantation. Therefore, long-term dual
ntiplatelet therapy may be required in some patients,
specially in anatomic subsets like left main coronary artery
tenting when subacute thrombosis could be lethal.
EW LESION SUBSETS. The pivotal randomized trials that
ed to approval of the Cypher and Taxus stents included
nly short, simple coronary lesions. The cost effectiveness of
ES in simple lesions was questioned in the Basel Stent
osten Effektivitats Trial (BASKET) (84). In this study,
36 patients were randomized to SES, PES, or cobalt-
hromium stents. Although the combined end point of
eath/myocardial infarction/TVR was lower at one year for
igure 2. Relationship between late loss and target lesion revascularization
olid triangles  sirolimus-, everolimus-eluting stent; open triangles 
ircles  bare metal stent. Target lesion revascularization is at nine month
evascularization at 12 months. 1  FUTURE-I*; 2  C-SIRIUS; 3
NDEAVOR-III; 8  ENDEAVOR-II; 9  TAXUS-IV; 10  SIRTA
roup)†; 13 TAXUS-VI; 14 TAXUS-V; 15DELIVER; 16 TAX
AXUS-II (moderate release group)†; 20  TAXUS-II (slow release
NDEAVOR-II; 25  SIRIUS; 26  C-SIRIUS; 27  TAXUS-VI; 2he DES patients (7.2% vs. 12.1%, p  0.02), the one-year sosts were significantly higher for the DES-treated patients.
ecause TVR rates were so low, the added costs of treating
ll low-risk patients was not overcome by less restenosis
nterventions at one year.
The year 2005 brought more data on complex lesion
ubsets that were not previously reported. In this regard, the
AXUS V trial reported by Stone et al. (85) and the
AXUS VI trial reported by Dawkins et al. (86) add new
nformation. Both trials randomized patients with long,
omplex coronary lesions. Stone et al. (85) reported a
eduction of nine-month TLR from 15.7% to 8.6% (p 
.001), and Dawkins et al. (86) reported a decrease in TLR
rom 18.9% to 6.8% (p  0.0001). No safety concerns were
eported. Similarly, the Stenting of Coronary Arteries in
on-Stress/Benestent Disease (SCANDSTENT) trial dem-
nstrated a significant reduction in TLR and MACE among
atients with complex coronary lesions who received an SES
ompared with a BMS (87).
Sabaté et al. (88) randomized 160 patients with diabetes
o treatment with BMS or SES. He found that angio-
raphic late lumen loss was significantly reduced by the
ypher stent (0.47  0.5 mm vs. 0.06  0.4 mm, p 
.001). There was no difference in efficacy for oral hypogly-
emic therapy or insulin-treated patients. Hermiller et al.
89) presented results of the PES in patients with diabetes
andomized in the TAXUS IV trial. Among the 318
atients (108 insulin dependent) studied, angiographic bi-
ary restenosis was reduced by 81% in PES-treated patients
34.5% vs. 6.4%, p  0.0001). Thus, both PES and SES
) in clinical trials evaluating bare metal and drug-eluting stent platforms.
olimus-eluting stent; solid squares  paclitaxel-drug-eluting stent; solid
ess indicated. *Target lesion revascularization at 6 months; †target lesion
RTAX; 4  ENDEAVOR-III; 5  SIRIUS; 6  E-SIRIUS; 7 
 TAXUS-II (slow release group)†; 12  TAXUS-II (moderate release
V; 17 BENESTENT (stent group); 18 STRESS (stent group); 19
p)†; 21  FUTURE-I; 22  TAXUS-V; 23  DELIVER; 24 
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April 18, 2006:1689–706 The Year in Interventional Cardiologyhese data are particularly important in light of the pow-
rful impact that diabetes has on restenosis. Among 11,484
atients enrolled in the Prevention of Restenosis with
ranilast and its Outcomes (PRESTO) trial, Singh et al.
90) found that diabetes, long lesions, ostial lesions, and
eft anterior descending coronary artery location signifi-
antly increased the risk for TVR in patients treated with
MS.
Because left anterior descending coronary artery lesion
ocation predisposes to restenosis, the efficacy of DES in
his location is of particular interest. Dangas et al. (91)
eported on the 536 patients in TAXUS IV who were
andomized to BMS or PES. Binary restenosis was reduced
rom 26.9% to 11.3% (p  0.004), and one-year MACE
vents were decreased from 21.2% to 13.5% (p  0.01).
eung et al. (92) studied use of the SES in the ostial left
nterior descending coronary artery location. In this con-
ecutive series, 68 patients with SES were compared with 77
atients treated with BMS before the two years prior to SES
vailability. Angiographic restenosis was lower with in the
ES group (5.1% vs. 32.3%, p  0.001). Importantly, no
eft main restenosis occurred with SES, whereas 7% of
MS-treated patients had left main restenosis. Finally,
sagalou et al. (93) reported on the 66 patients with left
nterior descending coronary artery-treated location that
ad 60 mm of stent length. They found a high incidence
f periprocedural myocardial infarction (17%), and a 15%
ate of TVR occurred. Thus, it appears that significant
rogress has been made in treatment of left anterior de-
cending coronary artery disease, but obstacles including
ajor side branch compromise and periprocedural myocar-
ial infarction still need to be overcome.
With the decline in the risk of restenosis, enormous
nthusiasm has risen for use of DES in patients with left
ain disease. Park et al. (94) reported on 102 patients
reated with SES from March 2003 to March 2004 and
ompared outcomes to historical controls treated with
MS. Their technical approach has changed in the DES
ra. More stents are used, more bifurcation disease is
reated, and less atherectomy debulking occurs. Impor-
antly, angiographic restenosis is lower (7.0% vs. 30.3%, p
.001), and freedom from MACE is higher (98% vs. 81%,
 0.0003) for patients treated with SES. The Thorax-
enter group reported similar results (95). Target vessel
evascularization rates were lower (6% vs. 23%, p  0.004)
n the 95 patients treated with DES compared with a
istorical control group of 86 patients treated with BMS.
imilarly, Chieffo et al. (96) found a lower rate of MACE
t six months in 85 patients who were treated with a DES
ompared with historical controls (20% vs. 35.5%, p 
.039). These three studies add great impetus for the
onduct of randomized trials of PCI with DES versus
ABG in this high-risk patient population.
In 2005, Valgimigli et al. (97) reported results of the first
andomized trial of DES in patients with AMI. A total of
75 patients were randomized to receive an SES plus firofiban or BMS plus abciximab. The primary study end
oint, a composite of death, non-fatal myocardial infarction,
troke, or binary restenosis, was significantly lower in the
ES group (19% vs. 50%, p  0.001), driven mainly by a
ower rate of binary restenosis in the DES group (9% vs.
6%, p  0.002). There was no difference in the incidence
f stent thrombosis. Although these data are promising,
arger studies are needed before routine use of DES for
atients with AMI can be recommended.
Additional lesion subsets that have shown good clinical
utcomes and low restenosis rates in studies include SVGs
98), ACS (99), in-stent restenosis (100), and CTO
101,102).
ES VERSUS BRACHYTHERAPY. Until recently, vascular
rachytherapy was the only effective treatment for patients
ith bare metal in-stent restenosis. The Sirolimus-Eluting
tent Versus Brachytherapy in Patients With Bare Metal
n-Stent Restenosis (SISR) trial, designed to compare the
fficacy of an SES versus brachytherapy, enrolled 384
atients with in-stent restenosis in native coronary arteries
103). Target vessel failure, the primary end point, was
ignificantly reduced in the SES group compared with
rachytherapy (12.4% vs. 21.6%, p  0.023). Angiographic
nalysis demonstrated greater distal edge late loss in the
rachytherapy group. Overall, these results indicate that use
f SES is superior to brachytherapy for the prevention of
ecurrent in-stent restenosis.
ew non–drug-coated stents. A novel strategy to limit
tent restenosis is the use of a titanium-nitride-oxide stent
oating. This material, which has a superior biocompatibil-
ty to stainless steel, has been shown in vitro to reduce
ascular inflammation and neointimal hyperplasia. In a
andomized trial reported this year, Windecker at al. (104)
ound that patients treated with a titanium-nitride-oxide
tent had a significantly lower late loss (0.55 mm vs. 0.90
m, p  0.03), binary restenosis (15% vs. 33%, p  0.07),
nd neointimal volume (18 vs. 48 mm3, p 0.0001) compared
ith patients who received a non-coated stent.
djunctive pharmacologic therapy to limit restenosis. Oral
edications to reduce restenosis may be of benefit. Cilosta-
ol (Otsuka American Pharmaceuticals, Rockville, Mary-
and), a platelet-aggregation inhibitor, appears to be a
eneficial adjunct for patients who are treated with a BMS
uring coronary revascularization. In the multicenter
ilostazol for Restenosis Trial (CREST), patients assigned
o cilostazol therapy had a significant reduction in angio-
raphic restenosis at six months (105). Importantly, a
enefit was also seen in subjects with diabetes and small
essels.
Pioglitazone (Takeda Pharmaceuticals, Osaka, Japan), an
ral diabetic agent, also appears to have antirestenotic
roperties. Marx et al. (106) randomized 50 patients with-
ut diabetes undergoing stent implantation to pioglitazone
30 mg/day) or placebo for six months. At six-month
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The Year in Interventional Cardiology April 18, 2006:1689–706antly reduced neointimal volume within the stented seg-
ent and lower binary restenosis rate compared with
ontrol patients (3.4% vs. 32.3%, p  0.01).
Zohlnhofer et al. (107) studied the use of systemic imatinib,
potent platelet-derived growth factor receptor kinase
nhibitor, for the prevention of recurrent restenosis in 180
atients with in-stent restenosis. Angiographic follow-up,
owever, demonstrated no difference in the rate of recurrent
estenosis.
MBOLIC PROTECTION DEVICES
he SPIDER trial evaluated a novel nitinol mesh filter
uring SVG intervention (108). One of the major advan-
ages of this filter is that the operator may cross the lesion
ith a conventional guidewire before deploying the protec-
ion device. The trial randomized 732 patients to undergo
CI with either the SPIDER (eV3, Plymouth, Minnesota)
evice or an approved control device (Fig. 3). At 30 days,
he primary study end point MACE occurred in 9.2% of
atients in the SPIDER arm and 8.7% of patients in the
ontrol arm (p  0.012 for non-inferiority). The Protection
uring Saphenous Vein Graft Intervention to Prevent
istal Embolization (PRIDE) trial compared the efficacy of
he TriActiv distal balloon occlusion system (Kensey Nash,
xton, Pennsylvania) with either the GuardWire
Medtronic) or FilterWire EX (Boston Scientific) devices
109). After PCI, there was no significant difference in the
ncidence of final TIMI flow grade 3 between the study
roups (TriActiv 99.1% vs. control group 97.8%, p  0.20).
t 30 days, the primary end point (MACE) was similar in
he TriActiv and control groups. These data suggest that
oth the SPIDER and TriActiv devices provide an equiv-
lent degree of embolic protection to currently available
istal protection systems.
Another method of limiting embolization during SVG
igure 3. Incidence of major adverse cardiac events at 30 days in six trials
W  FilterWire; GW  GuardWire.ntervention is to employ a proximal protection device. The sroximal Protection During Saphenous Vein Graft Inter-
ention Using the Proxis Embolic Protection System
PROXIMAL) trial was a non-inferiority trial, comparing
he Proxis system (St. Jude Medical, St. Paul, Minnesota) to
rotection with either the FilterWire or GuardWire distal
rotection devices (110). The 30-day MACE rate was 9.2%
n the Proxis arm and 10.0% in the control arm, suggesting
hat the proximal protection system provided equivalent
rotection to the distal devices. This system may be partic-
larly useful for patients in whom graft anatomy is not
uitable for use of a distal protection system.
Since the introduction of embolic protection systems,
here has been debate about the relative benefits of occlusive
ersus filter-based devices. Rogers et al. (111) performed a
orphometric analysis of particulate debris liberated during
VG intervention and found that the volume of embolic
aterial was equivalent between filter devices and distal or
roximal balloon occlusion devices. Finally, in a report from
he Saphenous vein graft Angioplasty Free of Emboli
andomized (SAFER) trial, Giugliano et al. (112) demon-
trated that the risk of distal embolization is independently
ssociated with more diffuse graft disease and bulkier
esions. However, the GuardWire device was also found to
e beneficial in patients with less extensive disease, suggest-
ng that embolic protection should be employed on a routine
asis during SVG intervention.
ORTIC AND CAROTID ARTERY DISEASE
his year further data emerged on the treatment of carotid
nd aortic disease. Long-term follow-up is now available
oncerning percutaneous repair of abdominal aortic aneu-
ysm. Initial reports describing early (30-day) outcome
uggested that the percutaneous approach had a safety
dvantage over open repair. In 2005, the Dutch Random-
zed Endovascular Aneurysm Management (DREAM)
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April 18, 2006:1689–706 The Year in Interventional Cardiologyneurysm Repair (EVAR) 1 study from Britain (114)
rovided long-term efficacy data. In the DREAM trial, 351
atients with abdominal aortic aneurysm 5 cm were
andomized and had two-year survival reported. Although
he stent group had an early survival advantage, at two years,
aplan-Meier survival probability was 89.6% versus 89.7%,
nd survival free of serious complications was 65.9% versus
5.6% (p  NS) for surgery versus stent therapy. Similarly,
he EVAR 1 investigators randomized 1,082 patients to
pen repair (n  543) or stent (n  539) therapy. At four
ears, mortality was 28% for both groups. Importantly,
ostoperative complications were 41% versus 9% for the
tent versus open repair (p  0.001), and costs were higher
or stent therapy. These two trials suggest that, in good
urgical candidates, no long-term survival advantage occurs
or stent graft therapy. Furthermore, stent graft therapy
equires detailed surveillance because a high percentage of
hese patients develop postoperative complications. Fi-
ally, the EVAR investigators also reported a random-
zed trial in 338 patients with abdominal aortic aneurysm
hat were not surgical candidates (115). As expected,
urvival with medical therapy was 64% in four years.
nfortunately, stent therapy did not improve survival. In
ummary, as of 2005, stent graft therapy offers no
ong-term survival advantage over open surgical repair of
bdominal aortic aneurysm and is associated with higher
ollow-up costs and complications. In poor surgical
andidates, this therapy still remains unproven.
In 2005, Rosenfield et al. (116) published a consensus
ocument on training and competence for performance of
arotid stenting. Casserly et al. (117) described the impact
f slow flow after carotid stenting. Slow angiographic flow
ccurred in 10% of 414 patients treated with carotid
tenting and distal protection devices. This had adverse
onsequences because post-operative stroke occurred in
.5% versus 1.7% (p  0.03) of these patients.
DJUNCTIVE PHARMACOLOGY
ntiplatelet therapy. STEMI/ACS. A meta-analysis of all
andomized trials of abciximab in AMI (involving 27,115
atients) found that abciximab reduced 30-day reinfarction
verall (2.1% vs. 3.3%, p  0.001), as well as in subgroups
reated with thrombolysis or with primary angioplasty
118). In the primary PCI group, abciximab treatment was
ssociated with reduced mortality at 30 days (2.4% vs. 3.4%,
 0.047) and long-term (6 to 12 months) (4.4%. vs. 6.2%,
 0.01) with no increased risk of major bleeding.
onversely, in thrombolytic-treated patients, abciximab did
ot reduce mortality but significantly increased the risk of
ajor bleeding (5.2% vs. 3.1%, p  0.001).
LECTIVE PCI. Although abciximab is beneficial in patients
ndergoing PCI for ACS or STEMI, it is not known
hether a 12-h infusion is necessary in elective PCI
atients, or whether a single bolus is adequate. The Same-
ay Home Discharge After Transradial Coronary Stenting vith a Single Abciximab Bolus (EASY) trial randomized
,005 patients who underwent transradial stent implanta-
ion with abciximab bolus, to receive either a 12-h abcix-
mab infusion and overnight hospitalization versus bolus
nly and discharge 4 to 6 h after PCI (119). Clinical
utcomes at 30 days and 6 months were similar between the
wo groups, and 88% of the bolus-only group was safely
ischarged the same day.
Some patients with definite indications for aspirin and
lopidogrel have a history of allergy to aspirin. Silberman et
l. (120) reported 16 patients with ACS who underwent
apid aspirin desensitization. Beta-blockers were withheld,
nd patients were monitored in the coronary care unit with
eak expiratory flow measured every 30 min along with vital
igns and visual allergy assessments. Patients underwent
apid desensitization over 2.5 to 3.5 h starting with low
oses of aspirin (1 to 5 mg), with doubling of the dose every
0 min until 80 to 100 mg was given. Successful tolerance
as induced in 93.5% of patients, allowing PCI and long-term
se of aspirin.
Clopidogrel “resistance” has been described in several
eports. Serebruary et al. (121) suggested that clopidogrel
esponse is not dichotomous, but followed a normal bell-
haped distribution in a study of 544 patients. The mean
esponse was 41.9  20.8% when platelet aggregation was
nduced by 5 mol/l of adenosine diphosphate. Hypore-
ponsiveness, defined as two standard deviations less than
he mean, occurred in 4.2% of patients.
The clinical implications of clopidogrel “hyporesponsive-
ess” were described in two reports. Gurbel et al. (122)
erformed platelet studies in 20 patients with subacute stent
hrombosis and compared them with 100 age-matched
ontrol patients without stent thrombosis. Subacute throm-
osis patients had incomplete P2Y12 receptor inhibition and
reater platelet aggregation to 5 mol/l adenosine diphos-
hate (49  4% vs. 33  2%, p  0.05). In another study
f 192 patients, platelet reactivity to adenosine diphosphate
as predictive of ischemic events post-PCI, but clot
trength (a measure of thrombin-induced fibrin and platelet
nteractions measured by thromboelastography) was the best
redictor of ischemic events (123).
What can be done to reduce platelet hyporesponsiveness?
n a randomized study of 190 patients, the incidence of
on-responsiveness (defined as 10% absolute change in
latelet aggregation) was reduced from 28% with 300-mg
oading dose of clopidogrel to 8% with a 600-mg dose (124).
nother randomized study of 60 patients confirmed that a
00-mg loading dose of clopidogrel resulted in higher
lasma concentrations of the active metabolite and less
latelet aggregation at 4 h compared with the 300-mg
oading dose (125). However, there was no additional
enefit to the 900-mg loading dose, suggesting limited
lopidogrel absorption. Hochholzer et al. (126) performed
latelet aggregation studies in 1,001 patients before 600 mg
lopidogrel and at the time of catheterization (performed at
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xpression of P-selectin, and activated glycoprotein IIb/
IIa) was achieved after 2 h. These data suggest that 600 mg
lopidogrel should be given instead of 300 mg, and admin-
stered at least 2 h before PCI.
The clinical relevance of different loading doses of
lopidogrel was assessed in the Antiplatelet Therapy for
eduction of Myocardial Damage during Angioplasty
ARMYDA)-2 study (127). These investigators random-
zed 255 patients undergoing PCI to 600 mg versus 300 mg
lopidogrel, given 4 to 8 h before PCI. Periprocedural
yocardial infarction was significantly lower in the group
hat received the 600-mg clopidogrel loading dose.
As expected, the addition of a glycoprotein IIb/IIIa agent
rovides greater platelet inhibition, compared with either
00 mg or 600 mg clopidogrel (128). Whether this will
ranslate to improved clinical outcomes has yet to be tested.
here is, however, evidence that triple versus dual antiplate-
et therapy is of clinical benefit. Lee et al. (129) reported an
bservational study of 3,012 stent patients, all of whom
eceived at least dual antiplatelet therapy with aspirin and
denosine diphosphate antagonist (clopidogrel or ticlopi-
ine, given more than two days in advance in 84% of
atients). Approximately half of the group received double
n  1,597) and the remainder triple antiplatelet therapy
n  1,415) (with an additional cilostazol 200-mg load
ollowed by 100 mg twice a day). No DES or glycoprotein
Ib/IIIa antagonists were utilized. Despite more multivessel
tenting and use of long stents in the triple antiplatelet
roup, stent thrombosis within one month was lower (0.1%
s. 0.5%, p  0.024). Predictors of stent thrombosis
ncluded primary stenting for AMI and not using cilostazol.
riple antiplatelet therapy was well tolerated with the
xception of a slight increase in skin rashes (1.1% vs. 0.5%,
 0.079). Given this observational report, as well as the
rospective, randomized CREST trial, consideration should
e given to adding cilostazol to patients at high risk of stent
hrombosis or restenosis.
Finally, the Joint Utilization of Medications to Block
latelets Optimally-Thrombolysis In Myocardial Infarction
6 (JUMBO-TIMI 26) trial evaluated the use of prasugrel,
able 3. Top-Ten “Must-Read” Published Studies in Interventio
Acronym
RMYDA-2 (127) Antiplatelet therapy for Reduction of MYo
RAVE-2 (8) Bavarian Reperfusion Alternatives Evaluat
APITAL-AMI (3) Combined Angioplasty and Pharmacologic
MERALD (22) Enhanced Myocardial Efficacy and Remov
IRSTLINE-AMI (28) Front-Integrated Revascularization and Ste
Colony-Stimulating Factor
CTUS (40) Invasive versus Conservative Treatment in
ROMISE (23) Protection Devices in PCI Treatment of M
EACT (2) Rescue Angioplasty versus conservative Tr
IRTAX (65)* Sirolimus-eluting and paclitaxel-eluting ste
AXUS-V (85) Comparison of a polymer-based paclitaxel-
diseaseWinner of the I2 Scientific Achievement award as the most impactful study in interventionovel thienopyridine P2Y(12) receptor antagonist, in
04 patients undergoing elective or urgent PCI (130).
rasugrel was found to be safe with no increased risk of
leeding complications compared with clopidogrel, and
here was a lower incidence of 30-day MACE in the
rasugrel group.
ntithrombin therapy. Because of the limitations of un-
ractionated heparin, several alternative antithrombotic
gents have been evaluated to improve the outcomes of PCI.
he Superior Yield of the New Strategy of Enoxaparin,
evascularization, and Glycoprotein IIB/IIA Inhibitors
SYNERGY) trial compared enoxaparin and unfractionated
eparin in high-risk patients with ACS who were expected
o undergo early invasive therapy. At 30 days, enoxaparin
as found to be non-inferior to unfractionated heparin in
educing death or non-fatal reinfarction. In 2005, the
ix-month and one-year outcomes of the SYNERGY trial
ere reported (131). At follow-up, there was a fairly high
ate of recurrent cardiac events; however, patients receiv-
ng enoxaparin had similar rates of death or myocardial
nfarction at six months (17.6% vs. 17.8%, p  NS) and
eath at one year (7.6% vs. 7.3%, p  NS) compared with
hose treated with unfractionated heparin.
Mehta et al. (132) reported results of a pilot study evaluating
se of intravenous fondaparinux in 350 patients during
lective or urgent PCI. The incidence of total bleeding was
imilar in patients treated with either fondaparinux or
eparin (6.4% vs. 7.7%, p  0.61), as was the composite
fficacy end point. Further studies with this novel anti-
hrombin agent are being planned.
onclusions. The year 2005 yielded dramatic advances in
he scientific body of evidence for interventional cardiology.
he Innovations in Intervention (I2) steering committee
as selected the ten most important published studies of
005 (Table 3). As expected, trials of mechanical reperfu-
ion and the comparative efficacy of DES dominate the list.
n addition, periprocedural pharmacotherapy is a crucial line
f investigation. We have had a preview of 2006 with the
ate Breaking Trials that were presented in 2005. More
etailed information on stem cell therapy is likely. Much
ore information on DES platforms, especially large, “real-
ardiology in 2005
Title
al Damage during Angioplasty
ervention versus Thrombolysis Alone in Acute Myocardial Infarction
Aspiration of Liberated Debris
ell Liberation in Evolving Acute Myocardial Infarction by Granulocyte
able Coronary Syndromes
rdial Infarction for Salvage of Endangered Myocardium
nt or Repeat Thrombolysis
r coronary revascularization
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April 18, 2006:1689–706 The Year in Interventional Cardiologyorld” registries will be forthcoming. Early, small random-
zed trials of DES versus CABG may appear, but the large
ivotal trials are still at least three years away. More carotid
tent registries will be published, but the pivotal CREST
rial is still far from completion. Finally, 2006 will likely
itness the start of a robust literature in percutaneous valve
herapy. Please stay tuned!
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ivision of Cardiology, William Beaumont Hospital, 3601 West
3 Mile Road, Royal Oak, Michigan 48073. E-mail: woneill@
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